Becton, Dickinson and Company (BDX) vs Merck & Co., Inc. (MRK)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| BDX | MRK | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Drug Manufacturers - General |
| Size band | LARGE | MEGA |
| Listing | NYSE | NYSE |
| Country | United States | United States |
| Theme | medical-devices | oncology |
| Price and returns | ||
| Last close | $196.39 | $140.61 |
| Return · 1 week | +2.96% | −2.10% |
| Return · 1 month | +6.83% | −5.43% |
| Return · 3 months | +18.07% | +6.67% |
| Return · year to date | +28.96% | +33.07% |
| Return · 1 year | +35.14% | +62.34% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −2.04% | −10.39% |
| 52-week high | $200.47 | $156.92 |
| 52-week low | $127.59 | $82.01 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $53.49B | $346.91B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $307.90M | $1.24B |
| Employees | 72,000 | 73,000 |
| Valuation | ||
| Price to earnings · trailing | 42.73× | 115.56× |
| Price to earnings · forward | 13.81× | 15.62× |
| Price to sales | 2.23× | 5.40× |
| Price to book | 2.05× | 8.57× |
| Enterprise value to EBITDA | 10.65× | 13.82× |
| Enterprise value to revenue | 2.90× | 6.00× |
| PEG ratio | 1.11 | 2.59 |
| Earnings per share · trailing | 4.30 | 1.26 |
| Profitability | ||
| Gross margin | 46.94% | 72.97% |
| Operating margin | 15.73% | −0.24% |
| Profit margin | 7.33% | 4.77% |
| Return on equity | 6.61% | 6.96% |
| Return on assets | 4.34% | 11.87% |
| Growth | ||
| Revenue growth | +5.40% | +5.10% |
| Earnings growth | −31.40% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 68.84 | 128.41 |
| Current ratio | 0.87 | 1.32 |
| Dividend yield | 2.33% | 2.38% |
| Payout ratio | 72.49% | 266.67% |
| Trend and volatility | ||
| RSI · 14 | 63.54 | 42.46 |
| ADX · 14 | 33.82 | 16.51 |
| 50-day average | $185.63 | $146.74 |
| 200-day average | $165.25 | $126.01 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.10% | 3.41% |
The full BDX analysis
Everything this table leaves out for Becton, Dickinson and Company: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the BDX argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full BDX analysisThe full MRK analysis
Everything this table leaves out for Merck & Co., Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the MRK argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full MRK analysis